Navigation Links
Cerulean Completes Enrollment of Randomized Phase 2 Study of CRLX101 in Non-Small Cell Lung Cancer
Date:7/2/2012

CAMBRIDGE, Mass., July 2, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC).  The company also announced that it has dosed the first patient in a second tumor type.

(Logo: http://photos.prnewswire.com/prnh/20120702/NE33542LOGO )

"Completing enrollment of our Phase 2 study is a significant company milestone and speaks to our team's ability to execute on the CRLX101 development program," said Oliver Fetzer, Ph.D., president and chief executive officer of Cerulean.  "CRLX101 is being evaluated to determine whether it can address the current treatment gap in NSCLC patients who are not likely to benefit from the approved molecularly targeted drugs.  We believe that the biological activity observed in our Phase 1 and Phase 2a studies is encouraging and supports the continued development of CRLX101 to evaluate whether it translates into clinical benefit for patients."

The fully-enrolled 150-patient randomized Phase 2 study is designed to assess the efficacy and safety of CRLX101 as a monotherapy for advanced NSCLC following one or two prior regimens of therapy.  The primary endpoint of the study is overall survival, and the patients will additionally be assessed for progression-free survival, tumor response, and pharmacokinetic parameters.  Final data from the study is expected by late 2012.

"The design of this trial has been well received and I am pleased to see that we were able to complete enrollment so quickly," said John Ryan, Ph.D., M.D., chair of the Medical Advisory Board of Cerulean.  "I al
'/>"/>

SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. InnoPharma Completes $15 Million Series A Financing
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. MiMedx Group Completes $5,000,000 Private Placement
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. Auxogyn Completes $20 Million In Series A Funding
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
11. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Philadelphia, PA (PRWEB) June 18, 2013 ... fiber-optic Ball Lenses engineered of synthetic Sapphire and Glass ... stock sizes from Swiss Jewel Company , of ... performance by expanding and collimating the light beams without ... extreme optical clarity and natural durability (9 mohs) make ...
(Date:6/18/2013)... WILMINGTON, Delaware , June 18, 2013 /PRNewswire/ ... to announce the release of the HELM biomolecular ... permissive open source MIT licence. HELM ... of a wide range of biomolecules (e.g. proteins, ... render existing small-molecule and sequence-based informatics methodologies impractical ...
(Date:6/18/2013)... Israel , June 18, 2013 ... Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage ... the company has been granted a United States ... US and Europe for the oral ... 8,410,176 B2 is titled Intermediate Compounds and Processes for ...
(Date:6/18/2013)... THE WOODLANDS, Texas , June 18, 2013 ... LXRX ), a biopharmaceutical company focused on ... that John Northcott has joined the ... strategy, and operations. Mr. Northcott brings extensive commercial ... on-market commercialization across a variety of therapeutic areas. ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3
... University of Wisconsin Medical Foundation is initiating ... Foundation's clinical data and to improve the reliability of ... QDX Platform V Integration Services from Quovadx, ... in Englewood, Colorado. , ,The Medical Foundations growth ...
... of single-molecule DNA analysis technology, announced Thursday it has commenced ... tumor, known as oligodendroglioma. OpGen, based in Madison, is working ... of genetics and chemistry at the University of Wisconsin-Madison and ... mapping, invented by Schwartz, will enable researchers to determine how ...
... weeks ago, I referred to offshore outsourcing as an ... an issue de lannee (an election year at that ... questions about the economic future of the U.S. Prominent ... the contenders for the Democratic presidential nomination to the ...
Cached Biology Technology:UW Medical Foundation Integrates Medical Records 2OpGen joins UW, Henry Ford Heath in Improving Brain Tumor Treatment 2The Great Offshore Outsourcing Debate 2
(Date:6/18/2013)... Adelaide shows that weight gain and increased head size in ... higher IQ at early school age. , The study was led ... more than 13,800 children who were born full-term. , The results, ... babies who put on 40% of their birthweight in the first ... they were six years of age, compared with babies who only ...
(Date:6/17/2013)... other locations with central nervous system infections may well ... virus, according to a study to be published in ... American Society for Microbiology. Researchers have detected the virus ... with central nervous system infections of unknown cause, and ... from pigs and poultry, suggesting animals may serve as ...
(Date:6/17/2013)... June 17, 2013 An international team led ... Howard Hughes Medical Institute and Albert Einstein College of ... new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium ... effort to help solve one of the major global ... its dangerous drug-resistant strains," said Peter G. Schultz, the ...
Breaking Biology News(10 mins):IQ link to baby's weight gain in first month 2New virus discovered in patients with central nervous system infections 2New virus discovered in patients with central nervous system infections 3New compound excels at killing persistent and drug-resistant tuberculosis 2New compound excels at killing persistent and drug-resistant tuberculosis 3New compound excels at killing persistent and drug-resistant tuberculosis 4
... CITY -- Climate change spells trouble for many tropical ... and relatively small areas and the damage will ... and competition among species. That is among the ... relevant to the topic. The review was scheduled for ...
... whether long periods of hot weather, such as last year,s ... or July, August or September? Scientists studying the subtle ... events happen makes a big difference. Based on more ... (NSF) Konza Prairie Long-Term Ecological Research (LTER) site in Kansas--one ...
... assistant professor of biochemistry at Virginia Tech, has ... administered by the Ministry of Science and Technology ... is "a significant contribution to the diagnosis and ... a release distributed my MICIT. Sobrado, an ...
Cached Biology News:Climate change threatens tropical birds 2Climate change threatens tropical birds 3Climate change threatens tropical birds 4Climate change threatens tropical birds 5Time of year important in projections of climate change effects on ecosystems 2Contributions to diagnosis, treatment of tropical diseases recognized 2
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
... Mouse monoclonal [HDAC8-48] to HDAC8 ... by several mechanisms such as DNA ... translational modifications of histones, which include ... epsilon-amino groups of lysine residues present ...
...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
Biology Products: